Biodexa Pharmaceuticals plc is a US-listed company in the biotechnology industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: data-quality checks not passed.
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Biodexa Pharmaceuticals plc valuation: adjust assumptions and compare models →
Biodexa Pharmaceuticals has little or no product revenue yet; it used $7m of cash in the twelve months. The diluted share count is up 1007.7% on a year earlier, which dilutes existing holders. It passes 2 of our 3 financial-health checks.
Our model value for Biodexa Pharmaceuticals is under review, so past values are not shown until it is resolved.
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Current signal Revenue growth decelerating: TTM revenue growth slowed to -45.2% (-53.9pp vs the prior quarter), the 2nd consecutive quarterly slowdown.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for BDRX from the sources we follow. See filings →
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
No analyst estimates are published for Biodexa Pharmaceuticals plc: too few analysts cover it.
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | $0.00 | $0.00 | 0.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY15 Q4 | $2.1M |
| FY16 Q4 | $1.8M |
| FY17 Q4 | $1.3M |
| FY18 Q4 | $2.6M |
| FY19 Q4 | $860.6K |
| FY20 Q4 | $440K |
| FY21 Q4 | $795.5K |
| FY22 Q4 | $864.7K |
| FY23 Q4 | $474K |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY16 Q4 | -14.7% |
| FY17 Q4 | -28.9% |
| FY18 Q4 | 103.1% |
| FY19 Q4 | -66.8% |
| FY20 Q4 | -48.9% |
| FY21 Q4 | 80.8% |
| FY22 Q4 | 8.7% |
| FY23 Q4 | -45.2% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY15 Q4 | -939.5% |
| FY16 Q4 | -729.6% |
| FY17 Q4 | -1342.4% |
| FY18 Q4 | -609.6% |
| FY19 Q4 | -1679.2% |
| FY20 Q4 | -6717.2% |
| FY21 Q4 | -1210.7% |
| FY22 Q4 | -1277.8% |
| FY23 Q4 | -2103.4% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY15 Q4 | -970.4% |
| FY16 Q4 | -1090.9% |
| FY17 Q4 | -1381.2% |
| FY18 Q4 | -706.6% |
| FY19 Q4 | -1008.8% |
| FY20 Q4 | -2772.6% |
| FY21 Q4 | -1094.8% |
| FY22 Q4 | -1017.2% |
| FY23 Q4 | -1798.4% |
| Fiscal year | 2015 Dec 2015 | 2016 Dec 2016 | 2017 Dec 2017 | 2018 Dec 2018 | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Income | |||||||||
| Revenue | 2 | 2 | 1 | 3 | 1 | 0 | 1 | 1 | 0 |
| Gross profit | 2 | 8 | 9 | — | — | — | — | — | — |
| EBITDA | −20 | −13 | −17 | −16 | — | — | — | — | — |
| Operating income | −20 | −13 | −17 | −16 | −14 | −30 | −10 | −11 | −10 |
| Net income | −15 | −27 | −21 | −20 | −13 | −28 | −8 | −9 | −9 |
| Diluted EPS | — | — | — | — | — | — | — | −$191753.91 | — |
| Growth (year on year) | |||||||||
| Revenue | — | −14.7% | −28.9% | +103.1% | −66.8% | −48.9% | +80.8% | +8.7% | −45.2% |
| Margins | |||||||||
| Gross margin | 94.9% | — | — | — | — | — | — | — | — |
| EBITDA margin | −954.8% | −727.9% | <−999% | −602.8% | — | — | — | — | — |
| Operating margin | −939.5% | −729.6% | <−999% | −609.6% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Net margin | −734.5% | <−999% | <−999% | −775.5% | <−999% | <−999% | −944.6% | <−999% | <−999% |
| Free-cash-flow margin | −970.4% | <−999% | <−999% | −706.6% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Cash flow | |||||||||
| Cash from operations | −19 | −18 | −17 | −18 | −8 | −12 | −8 | −9 | −8 |
| Capital spending | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −20 | −20 | −18 | −18 | −9 | −12 | −9 | −9 | −9 |
| Stock-based pay | 0 | 0 | 1 | −0 | −0 | −1 | 0 | 0 | 0 |
| Free cash flow after stock pay | −21 | −20 | −18 | −18 | −9 | −12 | −9 | −9 | −9 |
| Balance sheet | |||||||||
| Cash | 24 | 22 | 18 | 3 | 15 | 10 | 14 | 3 | 8 |
| Total debt | 2 | 2 | 8 | 1 | 8 | 0 | 1 | 1 | 0 |
| Net debt (negative = net cash) | −22 | −20 | −9 | −2 | −7 | −10 | −13 | −3 | −7 |
| Diluted shares | — | — | — | — | — | — | — | — | — |
| Last 12 months unless stated | BDRX | CRDF | CRVO | MNOV | STTK | CLNN | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $473962 | $508000 | $331295 | $920481 | $1m | $197000 | $55m |
| Revenue growth, last 12 months | −45.2% | −7.0% | −95.7% | 875.7% | −66.6% | −31.1% | 12.2% |
| Revenue growth, 3-year average | — | 7.2% | −52.7% | — | 5.2% | −36.9% | 13.7% |
| Revenue growth, latest quarter | — | −14.0% | −100.0% | 240.6% | −66.6% | 233.3% | 10.2% |
| Gross margin | 94.9% | 100.0% | 100.0% | 100.0% | — | 70.1% | 82.9% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −191.1% |
| Operating margin, 3-year average | <−999% | <−999% | <−999% | −905.8% | <−999% | <−999% | −365.3% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −172.8% |
| Cash from operations / revenue | <−999% | <−999% | <−999% | −989.7% | <−999% | <−999% | −168.8% |
| Free-cash-flow margin | <−999% | <−999% | — | −991.2% | <−999% | <−999% | −168.1% |
| Free-cash-flow margin, 3-year average | <−999% | <−999% | — | <−999% | <−999% | <−999% | −313.4% |
| Stock pay / revenue | 7.3% | >999% | 393.0% | 100.3% | 853.2% | >999% | 19.2% |
| Change in share count | >999% | 15.8% | 8.4% | 0.2% | 15.3% | 35.4% | 8.3% |
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Armistice Capital, LLC | $43,094 | 15K | 89.7% | New |
| Gamma Investing LLC | $3,501 | 1K | 7.3% | New |
| Allied Private Wealth LLC | $1,271 | 0K | 2.6% | — |
| Sbi Securities Co., Ltd. | $84 | 0K | 0.2% | ▼ 80.8% |
| UBS Group AG | $73 | 0K | 0.2% | New |
| Hilton Head Capital Partners, LLC | $17 | 0K | 0.0% | New |
| Caitong International Asset Management Co., Ltd | $15 | 0K | 0.0% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Biodexa Pharmaceuticals plc's complete shareholder register. Values are as reported by the filers .
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
